A Phase 1 interventional study of SEP-380135 and Placebo in Schizophrenia, Major Depressive Disorder (MDD) and Bipolar Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 3 of them phase 3. Schizophrenia · Otsuka Holdings Co., Ltd..
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 86th largest by enrollment of the 111 interventional ones that give a count, is the only one that started in 2024, is one of 34 in phase 1, and was the 120th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →3 of the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–74
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–55 · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 14 · Phase 3 54 · Phase 4 13
First in 1998; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 125 across the 111 interventional studies, 281 across the 8 observational. Of the 111 that completed or were terminated, 64 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
2 of the studies in Schizophrenia by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05325645Phase 3Otsuka Pharmaceutical Co., Ltd.Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia | 2027-09 |
| NCT07455084Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults | 2026-12-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple dose oral administration of SEP-380135 in participants with schizophrenia or with a major depressive episode associated with bipolar I or II disorder or major depressive disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other protocol-specified Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive SEP-380135 Dose Level 1, orally once daily (QD) from Day 1 to Day 14.
Drug: SEP-380135
Participants receive SEP-380135 Dose Level 2 orally once daily (QD) from Day 1 through Day 14.
Drug: SEP-380135
Participants receive SEP-380135 Dose Level 3 orally once daily (QD) from Day 1 through Day 14.
Drug: SEP-380135
Participants receive SEP-380135 Dose Level 4 orally once daily (QD) from Day 1 through Day 14.
Drug: SEP-380135
Participants receive SEP-380135 matching-placebo orally orally once daily (QD) from Day 1 to Day 14.
Drug: Placebo
oral capsule.
Placebo capsule.
All Cohorts: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Treatment Emergent Adverse Events (TEAEs) Leading to Trial Discontinuation
Time frame: Up to Day 44
All Cohorts: Percentage of Participants With Suicidal Ideation or Suicidal Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to Day 18
All Cohorts: Percentage of Participants With Withdrawal Symptoms Using the 20-Item Physician Withdrawal Checklist (PWC-20)
Time frame: Up to Day 44
All Cohorts: Percentage of Participants With Change From Baseline in Potentially Clinically Relevant Laboratory Tests
Time frame: Baseline, Day 18
All Cohorts: Percentage of Participants With Change From Baseline in Potentially Clinically Relevant Vital Signs
Time frame: Baseline, Day 18
All Cohorts: Percentage of Participants With Change From Baseline in Potentially Clinically Relevant Orthostatic Effects
Time frame: Baseline, Day 18
All Cohorts: Actual Values of Weight
Time frame: Up to Day 18
All Cohorts: Change From Baseline in Weight
Time frame: Baseline, Day 18
All Cohorts: Actual Values of Body Mass Index (BMI)
Time frame: Up to Day 18
All Cohorts: Change From Baseline in BMI
Time frame: Baseline, Day 18
All Cohorts: Actual Values of Waist Circumference
Time frame: Up to Day 18
All Cohorts: Change From Baseline in Waist Circumference
Time frame: Baseline, Day 18
All Cohorts: Percentage of Participants With Change From Baseline in 12-Lead Electrocardiogram (ECG)
Time frame: Baseline, Day 18
All Cohorts: Actual Values of QT interval corrected using Fridericia's Formula (QTcF)
Time frame: Up to Day 18
All Cohorts: Change From Baseline in QTcF
Time frame: Baseline, Day 18
Cohorts 1, 2, and 3: Actual Values of Clinician-Administered Dissociative States Scale (CADSS) Score
Time frame: Up to Day 18
Cohorts 1, 2, and 3: Change From Baseline in CADSS Score
Time frame: Baseline, Day 18
All Cohorts: Actual Values of Drug Effect Questionnaire (DEQ) Scored Using Visual Analog Scale Score
Time frame: Up to Day 18
All Cohorts: Change From Baseline in DEQ Scored Using Visual Analog Scale Score
Time frame: Baseline, Day 18
Cohorts 1, 2, and 3: Actual Values of Barnes Akathisia Rating Scale (BARS) Score
Time frame: Up to Day 18
Cohorts 1, 2, and 3: Change From Baseline in BARS Score
Time frame: Baseline, Day 18
Cohorts 1, 2, and 3: Actual Values of Abnormal Involuntary Movement Scale (AIMS) Score
Time frame: Up to Day 18
Cohorts 1, 2, and 3: Change From Baseline in AIMS Score
Time frame: Baseline, Day 18
Cohorts 1, 2, and 3: Actual Values of Simpson Angus Scale (SAS) Score
Time frame: Up to Day 18
Cohorts 1, 2, and 3: Change From Baseline in SAS Score
Time frame: Baseline, Day 18
Cohorts 1, 2, and 3: Actual Values of Positive and Negative Syndrome Scale (PANSS) Score
Time frame: Up to Day 18
Cohorts 1, 2, and 3: Change From Baseline in PANSS Score
Time frame: Baseline, Day 18
All Cohorts: Actual Values of Clinical Global Impressions-Severity Scale (CGI-S) Score
Time frame: Up to Day 18
All Cohorts: Change From Baseline in CGI-S Score
Time frame: Baseline, Day 18
Cohorts 1, 2, and 3: Actual Values of Calgary Depression Scale for Schizophrenia (CDSS) Score
Time frame: Up to Day 18
Cohorts 1, 2, and 3: Change From Baseline in CDSS Score
Time frame: Baseline, Day 18
All Cohorts: Percentage of Participants With Change From Baseline in Physical Examinations
Time frame: Baseline, Day 18
All Cohorts: Percentage of Participants With Change From Baseline in Neurological Examinations
Time frame: Baseline, Day 18
Cohort 4: Actual Values of Hamilton Anxiety Rating Scale (HAM-A) Score
Time frame: Up to Day 18
Cohort 4: Change From Baseline in HAM-A Score
Time frame: Baseline, Day 18
Cohort 4: Actual Values of Montgomery-Asberg Depression Rating Scale (MADRS) Score
Time frame: Up to Day 18
Cohort 4: Change From Baseline in MADRS Score
Time frame: Baseline, Day 18
Cohort 4: Actual Values of Young Mania Rating Scale (YMRS) Score
Time frame: Up to Day 18
Cohort 4: Change From Baseline in YMRS Score
Time frame: Baseline, Day 18
All Cohorts: Percentage of Participants With Changes in Quantitative Sleep Parameters Measured Using Electroencephalography (EEG)
Time frame: Up to Day 17
All Cohorts: Apparent Clearance (CL/F) of SEP-380135
Time frame: Day 14
All Cohorts: Volume of Distribution (Vz/F) of SEP-380135
Time frame: Day 14
All Cohorts: Maximum Plasma Concentration (Cmax) of SEP-380135
Time frame: Day 14
All Cohorts: Area Under the Drug Concentration-time Curve From Time Zero Predose to 24 hours Postdose (AUC0-24h) of SEP-380135
Time frame: Day 14
All Cohorts: Cmax of SEP-380135 and its Metabolites
Time frame: Days 1 and 14
All Cohorts: Time to Maximum Plasma Concentration (tmax) of SEP-380135 and its Metabolites
Time frame: Days 1 and 14
All Cohorts: AUC0-24h of SEP-380135 and its Metabolites
Time frame: Days 1 and 14
All Cohorts: Observed Plasma Concentration at 24 hours Postdose (C24h) of SEP-380135
Time frame: Days 1 and 14
All Cohorts: Terminal Phase Elimination Half-Life (t1/2,z) of SEP-380135 and its Metabolites
Time frame: Day 14
All Cohorts: Serum Concentration of SEP-380135 at Steady-State
Time frame: Day 14
Plan to share: Yes — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Nov 2024 to primary completion in Sep 2025, 10 months.
Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 10 months is above that.
Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otsuka Pharmaceutical Development & Commercialization, Inc. →